[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0FN2iTjnuZ4mr6HITVlnvzy7rjaPQAIQ6hHIVpqDmbY":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":19,"related":20,"source":30,"type":31},[],"2025-06-08 14:43:32",196298477,[8,9,10,11],"宣传安全性","宣传适应症","宣传治愈率","宣传疗效",{"count":13,"courseId":14,"courseImg":15,"courseName":16,"workId":17,"workName":18},246,"8e09f928906fdbfdc2fd50c78559fb3f","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F77e9e8ab3c7c2edfe53fbb2acf1fa6de.png","药事管理与法规","exam_159995740","项目四药品和药品管理认知","非处方药的广告宣传允许",[21,32,41,50,53,62,71,80,89,97],{"answer":22,"createTime":5,"id":23,"options":24,"question":29,"source":30,"type":31},[],196298465,[25,26,27,28],"生产工艺成熟","质量可控","质量稳定且可控","质量稳定且生产工艺成熟","非处方药的遴选原则中"质量稳定"是指","v1",0,{"answer":33,"createTime":5,"id":34,"options":35,"question":40,"source":30,"type":31},[],196298469,[36,37,38,39],"药品价格","药品销量","生产企业规模","安全隐患的严重程度","药品召回的分级依据是",{"answer":42,"createTime":5,"id":43,"options":44,"question":49,"source":30,"type":31},[],196298473,[45,46,47,48],"销售区域","省级媒体","无需公告","全国性媒体","三级药品召回应公告的范围是",{"answer":51,"createTime":5,"id":6,"options":52,"question":19,"source":30,"type":31},[],[8,9,10,11],{"answer":54,"createTime":5,"id":55,"options":56,"question":61,"source":30,"type":31},[],196298481,[57,58,59,60],"市级药品监管部门","省级药品监管部门","国家药监局","卫生行政部门","药品不良反应监测的行政管理机构不包括",{"answer":63,"createTime":5,"id":64,"options":65,"question":70,"source":30,"type":31},[],196298485,[66,67,68,69],"至少保存至药品有效期后五年","至少保存至药品有效期后三年","至少保存至药品有效期后两年","至少保存至药品有效期后一年","药品召回的记录保存期限是",{"answer":72,"createTime":5,"id":73,"options":74,"question":79,"source":30,"type":31},[],196298489,[75,76,77,78],"严重或罕见的不良反应","所有可疑不良反应","新的不良反应","严重、罕见或新的不良反应","列为国家重点监测的药品,应报告该药品引起的( )",{"answer":81,"createTime":5,"id":82,"options":83,"question":88,"source":30,"type":31},[],196298493,[84,85,86,87],"适应症超出说明书范围的药品","超过有效期的药品","药品成分不符合国家标准","以非药品冒充药品","下列哪种情形不视为假药",{"answer":90,"createTime":5,"id":91,"options":92,"question":96,"source":30,"type":31},[],196298498,[60,93,94,95],"国家药品不良反应监测中心","省级药品不良反应监测机构","市级药品不良反应监测机构","药品不良反应监测的技术管理机构不包括",{"answer":98,"createTime":5,"id":99,"options":100,"question":105,"source":30,"type":31},[],196298503,[101,102,103,104],"医疗机构协商","省级医保局确定","患者自付比例决定","国家统一规定","若新增一种抗癌药进入乙类目录,其支付比例由"]